(Q37346136)

English

ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension

scientific article published on 18 October 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension (English)

1 reference

Europe PubMed Central

19 August 2017

0 references

Alzheimer's disease

0 references

0 references

Craig W Ritchie

3

object named as

Craig W Ritchie

1 reference

Europe PubMed Central

19 August 2017

author name string

Laura M Gault

1

1 reference

Europe PubMed Central

19 August 2017

Robert A Lenz

2

1 reference

Europe PubMed Central

19 August 2017

Andreas Meier

4

1 reference

Europe PubMed Central

19 August 2017

Ahmed A Othman

5

1 reference

Europe PubMed Central

19 August 2017

Qi Tang

6

1 reference

Europe PubMed Central

19 August 2017

Scott Berry

7

1 reference

Europe PubMed Central

19 August 2017

Yili Pritchett

8

1 reference

Europe PubMed Central

19 August 2017

Weining Z Robieson

9

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

18 October 2016

1 reference

Europe PubMed Central

19 August 2017

Alzheimers Research & Therapy

1 reference

Europe PubMed Central

19 August 2017

8

1 reference

Europe PubMed Central

19 August 2017

1

1 reference

Europe PubMed Central

19 August 2017

44

1 reference

Europe PubMed Central

19 August 2017

https://scigraph.springernature.com/pub.10.1186/s13195-016-0210-1

0 references

Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

Acetylcholinesterase inhibitors: pharmacology and toxicology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

Alzheimer disease in the United States (2010-2050) estimated using the 2010 census

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

Cholinergic receptors: functional role of nicotinic ACh receptors in brain circuits and disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

α7 nicotinic acetylcholine receptors and their role in cognition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

Donepezil for dementia due to Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

Cornell Scale for Depression in Dementia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

“Mini-mental state”

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

Cerebral blood flow in dementia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

6 September 2017

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

14 September 2017

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

26 June 2018

A new rating scale for Alzheimer's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

26 June 2018

Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

2 September 2018

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

2 September 2018

Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

2 September 2018

Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

2 September 2018

Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

2 September 2018

Development of a new measure of health-related quality of life for people with dementia: DEMQOL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

2 September 2018

Development and testing of a new outcome measure of relationship between patients with Alzheimer's disease and their partners.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067903

2 September 2018

A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27756421

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S13195-016-0210-1

0 references

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37346136&oldid=2151382902"